留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

慢性乙型肝炎的抗病毒研究进展

操跃 钱其军

操跃, 钱其军. 慢性乙型肝炎的抗病毒研究进展[J]. 药学实践与服务, 2015, 33(6): 561-565. doi: 10.3969/j.issn.1006-0111.2015.06.022
引用本文: 操跃, 钱其军. 慢性乙型肝炎的抗病毒研究进展[J]. 药学实践与服务, 2015, 33(6): 561-565. doi: 10.3969/j.issn.1006-0111.2015.06.022
CAO Yue, QIAN Qijun. Progress in study of antiviral effect of chronic hepatitis B[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 561-565. doi: 10.3969/j.issn.1006-0111.2015.06.022
Citation: CAO Yue, QIAN Qijun. Progress in study of antiviral effect of chronic hepatitis B[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 561-565. doi: 10.3969/j.issn.1006-0111.2015.06.022

慢性乙型肝炎的抗病毒研究进展

doi: 10.3969/j.issn.1006-0111.2015.06.022

Progress in study of antiviral effect of chronic hepatitis B

  • 摘要: 慢性乙型肝炎是由乙型肝炎病毒(hepatitis B virus,HBV)引起的全球性传染病,HBV感染是我国肝硬化、原发性肝癌的重要原因。目前,干扰素类与核苷(酸)类似物抗病毒药物已广泛应用于临床,在一定程度上抑制了病毒的复制并控制了疾病的发展,但仍未从根本上清除病毒;各种治疗性疫苗在抗HBV方面也取得了一定疗效,但临床效果不佳。目前不少研究结果表明,生物免疫治疗可以成功清除体内的HBV,从而为乙肝的治疗带来新的希望。
  • [1] Robinson WS, Lutwick LI, et al. The virus of hepatitis, type B(fist of two parts)[J]. N Engl J Med,1976,295:1168-1175.
    [2] Ito K, Qin Y, Guarnieri M, et al.Impairment of hepatitis B virus virion secretion by single-amino-acid substitutions in the small envelope protein andrescue by a novel glycosylation site[J]. Virol,2010,84:12850-12861.
    [3] Shin D, Kim SI, Kim M, et al.Efficient inhibition of hepatitis B virus replication by small interfering RNAs targeted to the viral X gene inmice[J]. Virus Res,2006,119:146-153.
    [4] Roingeard P,Lu SL,Sureau C,et al.Immunocytochemical and electron microscopic study of hepatitis B virus antigen and complete particle production in hepatitis B virus DNA transfected HepG2 cells[J].Hepatology,1990,11(2):277-285.
    [5] Kanto T,Inoue M,Miyatake H,et al.Reduced number impaired ability of myeloid and plasmacytoid dendritic cell polarize T helper cells in chronic hepatitis C virus infection[J].J Infect Dis,2004,190(11):1919-1926.
    [6] van der Molen RG,Sprengers D,Binda RS,et al .Function impairment of myeloid and plasmacytoid dendritic cells tients with chronic hepatitis B[J].Hepatology,2004,40(3):738-746.
    [7] Stoop JN,van der Molen RG,Baan CC,et al.Regulatory cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection[J].Hepatology,2005,41(4):771-778.
    [8] Xu D,Fu J,Jin L,et al.Circulating and liver resident CD4,CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B[J].J Immunol, 2006,177(1):739-747.
    [9] Sandalova E,Laccabue D,Boni C,et al.Increased levels of arginase in patients with acute hepatitis B suppress antiviral T cells[J].Gastroenterology,2012,143(1):78-87.
    [10] Zhang Z,Zhang S,Zou Z,et al.Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients[J].Hepatology,2011,53(1):73-85.
    [11] Fattovich G, Stroffolini T, Zagni I,et al.Hepatocellular carcinoma in cirrhosis: incidence and risk factors[J]. Gastroenterology,2004,127(5 suppl 1): S35-S50.
    [12] Janssen HL, van Zonneveld M, Senturk H,et al.Pegylated interferon-alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B:arandomised trial[J].Lancet, 2005,365(9454):123-129.
    [13] Lau GK, Piratvisuth T, Luo KX,et al.Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B[J].N Engl J Med, 2005,352(26):2682-2695.
    [14] Dienstag JL.Drug therapy: hepatitis B virus infection[J].N Engl J Med,2008,359:1486-500.
    [15] Gish RG, Lok AS, Chang TT,et al. Entecavir therapy for up to 96 weeks inpatients with HBeAg-positive chronic hepatitis B[J]. Gastroenterology,2007,133: 1437-1444.
    [16] Zoutendijk R, Reijnders JG, Zoulim F,et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis[J]. Gut,2013,62: 760-765.
    [17] Barbaro G, Zechini F, Pellicelli AM, et al. Long-term efficacy of interferon-alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B.An Italian multicenter, randomized trial[J]. Hepatol,2001,35:406-411.
    [18] Petersen J, Ratziu V, Buti M,et al.Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study[J]. Hepatol,2012,56(3): 520-526.
    [19] Michel ML, Tiollais P. Hepatitis B vaccines: protective efficacy and the rapeutic potential[J].Pathol Biol,2010, 58(4):288-295.
    [20] Sheppard CW, Samar EP,Finely L,et al.Hepatitis B virus infection: epidemiol and vaccination[J].Epidemiol Rev,2006,28:112-125.
    [21] Chen HL, Chang MH, Ni YH, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan[J]. JAMA,1996, 276(11):906-908.
    [22] 贺学新.非核苷类似药物在慢性乙肝治疗中的应用[J].现代医药卫生,2008,24(5):717- 718.
    [23] Betaneourt AA.Phase I clinical trial in healthy adults of a nasalvaccine candidate containing recombinant hepatitis B surface and core antigens[J].Int J Infect Dis,2007,11(5):394-401.
    [24] Hu ZB, Liu Y, Zhai XJ, et al.New loci associated with chronic hepatitis B virus infection in Han Chinese[J].Nat Genet,2013,45(12):1499-1503.
    [25] Rehermann B.IntrahepaticT cells in Hepatitis B:viral control versus liver cell injury[J].J Exp Med,2000,191:1263-1268.
    [26] Bertoletti A,Ferrari C.Kinetics of the immune response during HBV and HCV infection[J].Hepatology,2003,38(1):4-13.
    [27] Shiina S, Fujino H, Uta Y, et al.Relationship of HBsAg subtypes with HBeAg/anti-HBe status and chronic liver disease. Part I: analysis of 1744 HBsAg carriers[J].Am J Gastroenterol, 1991,86(7):866-871.
    [28] Chen X, Tang Y, Zhang Y,et al.Peietal Tapasin modification on the intracellular epitope HBcAg18-27 enhances HBV-specific CTL immune response and inhibits hepatitis B virus replication in vivo[J].Lab Invest, 2014,94(5):478-490.
    [29] Pan XW, Ding HG, Zhou XY,et al.Identification of hepatitis B virus-specific CTL epitopes presented by HLA-A*33:03 in peripheral blood mononuclear cells from patients and transgenic mice[J].Biochem Biophys Res Commun,2014,449:135-140.
    [30] Ito H, Hoshi M, Ohtaki H,et al. Ability of IDO to attenuate liver injury in a-galactosylceramide-induced hepatitis model[J].J Immunol,2010,185(8):4554-4560.
    [31] Ito H, Seishima M. Regulation of the induction and function of cytotoxic T lymphocytes by natural killer T cell[J]. Biomed Biotechnol,2010,10:641-757.
    [32] Kim D, Hung CF, Wu TC,et al. DNA vaccine with a-galactosylceramide at primephase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells[J]. Vaccine,2010, 28:7297-305.
    [33] Ito H, Ando K, Ishikawa T, et al. Role of Va14+ NKT cells in the development of hepatitis B virus-specific CTL: activation of Va14+ NKT cells promotes the breakage of CTL tolerance[J]. Int Immunol,2008,20:869-879.
    [34] Akbar SM, Chen S, Al-Mahtab M, et al. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccinesin a murine model of chronic hepatitis B: HBcAg is a candidate for atherapeutic vaccine against hepatitis B virus[J]. Antiviral Res,2012,96:59-64.
    [35] Chen W, Shi M, Shi F, et al. HBcAg-pulsed dendritic cell vaccine induces Th1 polarization and production of hepatitis B virus-specific cytotoxic T lymphocytes[J]. Hepatol Res,2009,39:355-365.
    [36] Chen X, Liu H, Tang Z, et al. The modification of Tapasin enhances cytotoxic T lymphocyte activity of intracellular delivered CTL epitopes via cytoplasmic transduction peptide[J]. Acta Biochim Biophys Sin(ABBS,Shanghai), 2013,45(3):203-212.
  • [1] 沈启刚, 韩宗儒, 闵晓春, 姚勤, 马维娜.  中医辨证联合恩替卡韦治疗慢性乙型肝炎的临床疗效观察 . 药学实践与服务, 2020, 38(2): 170-173. doi: 10.3969/j.issn.1006-0111.201904148
    [2] 邬亚妙, 姜秀浓.  腺苷蛋氨酸治疗慢性乙型肝炎伴胆红素升高疗效观察 . 药学实践与服务, 2015, 33(5): 457-459. doi: 10.3969/j.issn.1006-0111.2015.05.021
    [3] 林惊世.  3种核苷类似物治疗慢性乙型肝炎的成本-效果分析 . 药学实践与服务, 2011, 29(6): 475-477.
    [4] 于洪亮, 唐立尧, 魏斌.  4种常见中药治疗乙肝的研究进展 . 药学实践与服务, 2006, (1): 31-34.
    [5] 徐国华, 雷招宝.  治疗慢性丙型肝炎新药——聚乙二醇干扰素α-2b . 药学实践与服务, 2005, (6): 350-353.
    [6] 劳国琴, 唐志华, 王佳良.  4种慢性乙型肝炎治疗方案的成本-效果分析 . 药学实践与服务, 2004, (6): 374-376.
    [7] 张夏华, 龚守军, 吴征.  乙肝康治疗慢性乙型肝炎近期疗效分析 . 药学实践与服务, 2004, (3): 148-149.
    [8] 顾晶晶, 田桂珍.  拉米夫定联合苦参素治疗慢性乙型肝炎的临床疗效 . 药学实践与服务, 2003, (1): 3-4.
    [9] 吴诚, 钟延强, 刘善奎.  干扰素缓释给药系统的研究进展 . 药学实践与服务, 2003, (2): 87-89.
    [10] 张晓莉, 田桂珍, 顾晶晶.  疗尔健(Hepadif)治疗慢性乙型肝炎临床观察 . 药学实践与服务, 2001, (5): 262-263.
    [11] 王雪, 陈泽莲.  干扰素口含片及其它非注射用干扰素制剂的研究进展及临床应用 . 药学实践与服务, 1999, (5): 274-275.
    [12] 郭德玉, 程珊, 李秀兰.  干扰素与聚肌胞合用对乙型肝炎30例HBV转归疗效观察 . 药学实践与服务, 1999, (2): 121-121.
    [13] 林剑梅, 黄啸坤, 范丽萍.  干扰素滴眼液辅助治疗尖锐湿疣 . 药学实践与服务, 1999, (6): 328-329.
    [14] 杨以真, 蔡修熙.  干扰素不适用于流行性腮腺炎的治疗 . 药学实践与服务, 1998, (5): 281-282.
    [15] 朱光文, 李东.  四君子汤加减治疗难治性慢性乙型肝炎33例疗效观察 . 药学实践与服务, 1997, (2): 82-83.
    [16] 高乃武, 李汉章.  乙肝Ⅰ号治疗慢性乙型肝炎疗效观察 . 药学实践与服务, 1997, (1): 9-10.
    [17] 何仁贵, 卢存运.  猪苓多糖注射液合用乙型肝炎疫苗对慢性乙型肝炎的疗效观察 . 药学实践与服务, 1996, (3): 142-144.
    [18] 刘丽萍, 徐丽芬.  基因工程干扰素治疗乙型病毒性肝炎34例的近期疗效和不良反应观察 . 药学实践与服务, 1995, (5): 271-272.
    [19] 陆定奕.  中草药治疗乙型肝炎的应用研究 . 药学实践与服务, 1994, (4): 21-24.
    [20] 刘能德, 刘波, 徐初洪.  国外干扰素治疗作用研究的近年报道 . 药学实践与服务, 1990, (1): 9-10.
  • 加载中
计量
  • 文章访问数:  2715
  • HTML全文浏览量:  254
  • PDF下载量:  336
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-02-10
  • 修回日期:  2015-07-13

慢性乙型肝炎的抗病毒研究进展

doi: 10.3969/j.issn.1006-0111.2015.06.022

摘要: 慢性乙型肝炎是由乙型肝炎病毒(hepatitis B virus,HBV)引起的全球性传染病,HBV感染是我国肝硬化、原发性肝癌的重要原因。目前,干扰素类与核苷(酸)类似物抗病毒药物已广泛应用于临床,在一定程度上抑制了病毒的复制并控制了疾病的发展,但仍未从根本上清除病毒;各种治疗性疫苗在抗HBV方面也取得了一定疗效,但临床效果不佳。目前不少研究结果表明,生物免疫治疗可以成功清除体内的HBV,从而为乙肝的治疗带来新的希望。

English Abstract

操跃, 钱其军. 慢性乙型肝炎的抗病毒研究进展[J]. 药学实践与服务, 2015, 33(6): 561-565. doi: 10.3969/j.issn.1006-0111.2015.06.022
引用本文: 操跃, 钱其军. 慢性乙型肝炎的抗病毒研究进展[J]. 药学实践与服务, 2015, 33(6): 561-565. doi: 10.3969/j.issn.1006-0111.2015.06.022
CAO Yue, QIAN Qijun. Progress in study of antiviral effect of chronic hepatitis B[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 561-565. doi: 10.3969/j.issn.1006-0111.2015.06.022
Citation: CAO Yue, QIAN Qijun. Progress in study of antiviral effect of chronic hepatitis B[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 561-565. doi: 10.3969/j.issn.1006-0111.2015.06.022
参考文献 (36)

目录

    /

    返回文章
    返回